Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine

I S Batth; A Mitra; S Manier; I M Ghobrial; D Menter; S Kopetz; S Li

doi:10.1093/annonc/mdw619

Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine

Ann Oncol. 2017 Mar 1;28(3):468-477. doi: 10.1093/annonc/mdw619.

Authors

I S Batth¹, A Mitra¹, S Manier², I M Ghobrial², D Menter³, S Kopetz³, S Li¹

Affiliations

¹ Department of Pediatrics - Research, The University of Texas MD Anderson Cancer Center, Houston, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
³ Department of Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.

Abstract

Current trajectory of clinical care is heading in the direction of personalized medicine. In an ideal scenario, clinicians can obtain extensive diagnostic and prognostic information via minimally-invasive assays. Information available in the peripheral blood has the potential to bring us closer to this goal. In this review we highlight the contributions of circulating tumor cells and circulating tumor DNA and RNA (ctDNA/ctRNA) towards cancer therapeutic field. We discuss clinical relevance, summarize available and upcoming technologies, and hypothesize how future care could be impacted by a combined study.

Keywords: cell free DNA; cell free RNA; circulating tumor DNA; circulating tumor RNA; circulating tumor cells; exosomes.

Publication types

Review
Research Support, N.I.H., Extramural

MeSH terms

Biomarkers, Tumor / blood*
Circulating Tumor DNA / blood*
DNA, Neoplasm / genetics
Humans
Mutation
Neoplasms / blood*
Neoplasms / genetics
Neoplastic Cells, Circulating / metabolism*
Precision Medicine

Substances

Biomarkers, Tumor
Circulating Tumor DNA
DNA, Neoplasm

Abstract

Publication types

MeSH terms

Substances

Grants and funding